refractory chronic lymphocytic leukemia
Showing 1 - 25 of >10,000
Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)
Not yet recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Zhengzhou, Nanjing (TQB3909 tablet)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- TQB3909 tablet
-
Zhengzhou, Henan, China
- +1 more
Jul 17, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Chronic Lymphocytic Leukemia Trial in Salt Lake City (RP-3500 in combination with Olaparib)
Recruiting
- Chronic Lymphocytic Leukemia
- RP-3500 in combination with Olaparib
-
Salt Lake City, UtahHuntsman Cancer Institute at the University of Utah
Sep 23, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +4 more
- Daratumumab
- Ibrutinib
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Duarte, California
- +2 more
Oct 7, 2022
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt
Active, not recruiting
- Prolymphocytic Leukemia
- +4 more
- Selinexor
- +3 more
-
Columbus, Ohio
- +1 more
Apr 29, 2022
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Recruiting
- Chronic Lymphocytic Leukemia
- +4 more
-
Bobigny, France
- +8 more
Mar 23, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Chronic Lymphocytic Leukemia Trial in Milano (Venetoclax, Imbruvica Oral Product)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Venetoclax
- Imbruvica Oral Product
-
Milano, MI, ItalyOspedale San Raffaele
Apr 2, 2022
Chronic Lymphocytic Leukemia Trial in Poland, United Kingdom (Ceralasertib, Acalabrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
-
Kraków, Poland
- +10 more
Dec 2, 2022
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)
Terminated
- Chronic Lymphocytic Leukemia(CLL)
- Small Lymphocytic Lymphoma
-
Hackensack, New JerseyHackensack University Medical Center
Jun 24, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)
Withdrawn
- Chronic Lymphocytic Leukemia
- +8 more
- Dose combination 1-1
- +5 more
- (no location specified)
Nov 1, 2021
Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Richter Syndrome
-
Miami, Florida
- +6 more
Jan 6, 2023
Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Completed
- Loss of Chromosome 17p
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 4, 2022
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial
Active, not recruiting
- Contiguous Stage II Small Lymphocytic Lymphoma
- +11 more
- MOR00208
- +2 more
-
Columbus, OhioThe Ohio State University Comprehensive Cancer Center
Feb 24, 2022
Chronic Lymphocytic Leukemia Trial in Boston, Rochester, Durham (Obinutuzumab, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
-
Boston, Massachusetts
- +3 more
Jan 3, 2022